Surrogate indicators have often been used to estimate intravascular volume to guide fluid management. Brain-type natriuretic peptide (BNP) has been used as a noninvasive adjunct in the diagnosis of fluid overload and as a marker of response to therapy, especially in individuals with congestive heart failure. Similarly, right ventricular end-diastolic volume index (RVEDVI) measurements represent another parameter used to guide fluid resuscitation. The aim of this study was to evaluate whether BNP and RVEDVI are clinically valuable parameters that can distinguish among hypovolemia, euvolemia, and hypervolemia, as measured by blood volume (BV) analysis in critically ill surgical subjects.
T he maintenance of euvolemia in intensive care unit (ICU) patients is fundamental to the optimization of cardiac output, tissue perfusion, and ultimately, the delivery of oxygen to tissues. Directly measuring circulating blood volume (BV) may provide valuable insight into intravascular volume status, while at the same time furnishing a practical means to judiciously guide fluid management. Assessing and monitoring the dynamic changes that occur in intravascular volume in this patient cohort are challenging because of the paucity of existing methodology that takes into account the extravascular fluid shifts that attend active fluid resuscitation. 1Y6 In this context, the combined double-radioisotope dilution technique using radiolabeled albumin and chromium 51Ytagged red blood cells has traditionally been the reference method for BV measurement. The clinical applicability of this modality had been extremely limited in the ICU setting owing to both arduous methodology and an inordinate delay in obtaining timely results. 2 Technologic innovations have made BV measurements in real time more feasible and useful with the development of the semiautomated, Food and Drug AdministrationYapproved BVA-100 Blood Volume Analyzer (Daxor Corporation, Inc., New York, NY). Several studies have demonstrated that the BVA-100 Analyzer significantly reduces the duration and complexity of BV measurements with preliminary results available within 40 minutes. 2,6Y8 This enhancement provides point-of-care testing that is now practical and generalizable to the ICU sector.
Conventional surrogate markers often used to collectively estimate the intravascular volume status of a patient include laboratory values (hematocrit [Hct] , electrolytes, blood urea nitrogen, and creatinine) and bedside clinical parameters (heart rate [HR], blood pressure, urine output, and the presence or absence of peripheral edema) that may or may not be integrated with hemodynamic and volumetric data obtained from pulmonary artery catheters (PACs), and pulse-contour continuous cardiac output monitoring.
2,9Y11 Because of their availability and ease of use, these systems have been, with the relatively recent exception of PAC, widely used in the ICU to guide fluid management. 12Y15 Vincent et al. 14,15 provided a thoughtful summary on possible causes for the lack of benefit of PAC and stressed the importance of correct measurement, correct interpretation, and correct application. They concluded that PAC are still a valuable tool for hemodynamic monitoring when used in selected patients and by physicians adequately trained to correctly interpret and apply the data provided. Our group has used PAC-guided goals of oxygen delivery to an end point of adequate tissue oxygenation parameters and have demonstrated improved survival in a prospective randomized trial. 1 There are, however, conflicting perspectives in the scientific literature. Rajaram et al. 13 in a 2013 Cochrane Review concluded that the use of PAC did not alter the outcomes of adult patients in the ICU but that these investigators nonetheless recommended that newer, less invasive, hemodynamic monitoring tools should be validated against PAC before clinical use in critically ill patients.
Within this framework, existing literature that has built upon previous attempts to clinically estimate a patient's intravascular volume status reports on several, more recently used surrogate markers that may provide improved estimation of a patient's BV. Two of these markers include serum brain-type natriuretic peptide (BNP) and right ventricular end-diastolic volume index (RVEDVI). 8, 16 BNP is a neurohormone produced by the ventricles of the heart in response to myocardial stretch (as may occur with intravascular volume expansion and increased wall tension), proinflammatory cytokines, norepinephrine, glucocorticoids, elevated angiotensin II concentration, myocardial ischemia, and inotropic agents.
17Y20 Its physiologic role is to stimulate vasodilation, natriuresis, diuresis, and inhibition of renin release in response to myocardial distension.
20Y23 Serum BNP may have value in the clinical setting, as an indirect estimate of intravascular volume status. 17Y23 Friese et al., 17 showed that serum BNP levels after injury increase with volume resuscitation and that this measure may serve as a biomarker for preload status during resuscitation in trauma patients. Chircop and Jelinek 24 found that a BNP level of 500 pg/mL retains its diagnostic ability with a positive predictive value of 90% in ruling in heart failure. In contrast, Omland 21 in a review of BNP in the evaluation of acute heart failure points out that the correlation between BNP and pulmonary artery occlusion pressure (PAOP) or left ventricular end-diastolic pressures are only moderately strong, not permitting reliable information to be obtained regarding filling pressures.
The RVEDVI is calculated from the right ventricular ejection fraction and cardiac index (CI) by dividing the stroke volume index (CI divided by HR) by the right ventricular ejection fraction. It is an accurate indicator of preload volume in the right ventricle. Notably, this cardiac parameter has been shown to be more closely correlated to CI than the traditionally used parameter of left ventricular preload, the PAOP, in patients with sepsis, adult respiratory distress syndrome (ARDS), traumatic injuries, and in those receiving mechanical ventilation. 10, 25, 26 Diebel et al. 27 have shown that trauma patients with RVEDVI of less than 90 mL/m 2 had a positive hemodynamic response to fluid resuscitation with an increase in CI, whereas those with values greater than 140 mL/m 2 did not. Other investigators have reported similar findings. 25 Despite the widespread use of BNP and RVEDVI as indirect measures of cardiac preload, there is limited research on the value of these markers in predicting true circulating BV in the ICU population. The specific aim of this study was to determine whether BNP and RVEDVI are accurate surrogate predictors of intravascular volume, as directly measured by the BVA-100 Analyzer.
PATIENTS AND METHODS
The Research and Institutional Review Committee (Institutional Review Board equivalent) of The Queen's Medical Center, a university-affiliated, tertiary care, teaching hospital, reviewed and approved this study before implementation. Written informed consent to participate in the study was obtained from all subjects or from a legal surrogate. This observational study was a planned side arm of a prospective, randomized controlled trial using PAC values compared with PAC + BV values to guide fluid and blood component transfusion management.
2 Study subjects were recruited from consecutive patients admitted to the ICU, who were randomized to either a control group (fluid management guided by PAC parameters) or a BV group (fluid management guided by BV results in addition to PAC parameters). 1 Subjects were excluded if they had surrogates who were unable or unwilling to provide consent, if they were younger than 18 years, were pregnant, or had brain injury documented on computed tomography with a Glasgow Coma Scale (GCS) score of 12 or less, quadriplegia, do-not-resuscitate status, height less than 122 cm or greater than 218 cm, and weight less than 21.3 kg or greater than 379 kg in men and greater than 351 kg in women. Subjects were excluded at these extremes of height and weight given that the accuracy of the BVA-100 Analyzer has not been validated in these ranges, based on the manufacturer's guidelines. Subjects with traumatic brain injury were excluded because this cohort of ICU admissions is comanaged with our neurointensivists, and a different resuscitation protocol is applied to this group of subjects.
Patients with the following diagnoses were enrolled: (1) traumatic injuries and (2) postsurgical conditions requiring ICU care for fluid resuscitation and hemodynamic monitoringVlow blood pressure (systolic blood pressure G 90 mm Hg despite adequate fluid resuscitation to a PAOP of 15Y18 mm Hg), persistent tachycardia (defined as HR 9 100 beats/min), low urine output (G0.5 mL/kg/h despite volume infusion), worsening renal function (serum creatinine increase of 920% of baseline), low CI (G2.5 L/min/m 2 with PAOPs of 15Y18 mm Hg), poor oxygenation (PaO 2 /FIO 2 ratio G200 or Qs/Qt ratio 920%), persistent requirement for vasopressors or nonnormalization of lactate levels, (3) septic shock, (4) severe sepsis, (5) cardiovascular collapse, and (6) ARDS. The criteria for these diagnoses have already been described elsewhere. 1, 2, 28 Baseline and demographic data were collected, which included HR, arterial blood pressure, urinary output, PAC data (including RVEDVI), chest radiograph interpretation, arterial blood glass analysis, BNP, lactic acid, blood urea nitrogen, creatinine, and hemoglobin/Hct concentrations as previously reported. 1 The RVEDVI data were collected simultaneously with the BV analysis. The BNP data were obtained within 0 hour to 6 hours of the RVEDVI and BV measurements.
All BV measurements were performed within the first 12 hours to 24 hours after acute resuscitation was completed, to avoid confounding of data during BV analysis that may result from nonYsteady states associated with large-volume resuscitation. More specifically, exclusion of subjects during the first 12 hours to 24 hours of resuscitation was performed to minimize any impact that rapidly shifting intravascular volumes, vasopressor, or inotrope use may exert on BV analysis.
1,2,28
The start time of resuscitation was defined as the time of PAC insertion or the time of ICU arrival if the subject came with a PAC that had been inserted in the operating room. The goals of resuscitation for all subjects have been described previously and include systolic blood pressure greater than 100 mm Hg or within 40 mm Hg from known baseline, HR of less than 100 beats/min, urinary output of greater than 0.5 mL/kg/h, lactate to normal values, oxygen delivery adequate to achieve SvO2 of 70% or greater. 1 After these end points of resuscitation were achieved and during the subsequent period of BV analysis, subjects were maintained on a constant crystalloid infusion rate and were not given crystalloid boluses, colloid, blood transfusions, or diuretics; vasopressor or inotropic agents were not started during this period. If subjects were on vasopressor or inotropic agents, the infusion rates were kept constant during the period of BV measurement. 1 BV assessment was performed with the BVA-100 Blood Volume Analyzer. After obtaining a baseline sample of 5 mL of blood and a simultaneous Hct, a tracer consisting of human serum albumin tagged with I-131 (5Y30 HCi) was injected intravenously over 1 minute and allowed to mix completely throughout the subject's circulation for 12 minutes. To correct for albumin transudation, serial blood measurements of 5 mL were collected at 12, 18, 24, 30, and 36 minutes postYalbumin I-131 injection and extrapolated to time zero to calculate the plasma volume (PV). Radioactivity was measured in duplicate in a semiautomated counter, and a minimum of three samples with an SD of less than 3.9% were used to calculate PV. The red blood cell volume (RBCV) was then derived based on the calculation Hct = RBCV / RBCV + PV. Total BV = PV + RBCV. To interpret the results, the RBCV, PV, and total BV were compared with subjects ''ideal or normal'' volumes to account for size differences. Results were available within 40 minutes. The limitations of using the historical estimation of total BV of 60 mL/kg to 70 mL/kg have long been recognized, especially at the extremes of subject weight. 29 The BVA-100 calculates the subject's ideal or normal BVusing an established algorithm based on sex, height, baseline weight, and deviation from optimum longevity-related weight as determined by the Metropolitan Life Tables and as previously validated by BV studies. 6, 8, 9, 30 This mathematical model is more accurate than using either the body surface area or a subject's weight, particularly at the extremes of weight. Quite the opposite, fixed weight ratio and body surface area norms revealed systematic errors or wide scatter. Subject age has not been demonstrated to be a factor in BV analysis using the methodology in this study. 8, 9, 28, 30 BV results were then categorized and presented as percent deviation from the individual's ideal BV (Table 1) . Based on reference ranges, hypovolemia was defined as less than 0%, euvolemia was defined as 0% to +16%, and hypervolemia was defined as greater than +16% deviation from ideal BV. A BNP of greater than 500 pg/mL was selected as the threshold value indicative of hypervolemia for statistical analysis, given the reported strong correlation of BNP concentrations at this level with myocardial stretch and heart failure in the peer-reviewed literature. 24 RVEDVI value of 140 mL/m 2 or less was selected as the threshold value indicative of euvolemia, in the framework of evidence-based data, which demonstrates no clinical benefit of further fluid resuscitation beyond this value. 31 Excel 2010 Microsoft (Redmond, WA) was used for statistical analysis. Data analysis using the Fisher's exact test and univariate linear regression analysis was performed to investigate the relationship of BNP concentrations and RVEDVI with hypovolemia, hypervolemia, and euvolemia as determined by BV analysis. Statistical significance was defined as p e 0.05.
RESULTS
Eighty-one subjects were included in this study. Of the subjects, 33 were female and 48 subjects were male. Forty-two percent of the subjects had septic shock/severe sepsis. The mortality rate of this cohort was 17%. Subject demographics are presented in Table 2 . Intravascular BV results, BNP, and RVEDVI measurements are summarized in Table 3 .
Of the 81 subjects, 16 were hypovolemic, 32 were euvolemic, and 34 were hypervolemic based on BV analysis. Among the 39 subjects with a BNP level greater than 500 pg/mL, 6 were hypovolemic, 18 were euvolemic, and 15 were hypervolemic (10) ( Table 3 ). There was no statistically significant difference in hypervolemic subjects between those with BNP of greater than 500 pg/mL and in those with BNP of 500 pg/mL or less ( p = 0.82). Similarly, no statistically significant difference was observed between subjects with BNP levels of 500 pg/mL or less and greater than 500 pg/mL in the euvolemic and hypovolemic cohorts ( p = 0.26 and p = 0.41, respectively).
Of the 81 subjects in this study, 19 had an RVEDVI greater than 140 mL/m 2 . Of these 19 subjects, 5 were hypovolemic, 8 were euvolemic, and 6 were hypervolemic (Table 3) . No statistically significant relationships were found among hypovolemic, euvolemic, and hypervolemic subjects and RVEDVI of 140 mL/m 2 or less or greater than 140 mL/m 2 ( p = 0.51, p = 0.79, and p = 0.43, respectively).
A strong correlation was not demonstrated between BNP and BV, with a coefficient of determination of 0.085 ( p = 0.45) (Fig. 1) . Similarly, no linear relationship was found between RVEDVI and BV (R = 0.290, p G 0.009) (Fig. 2) .
DISCUSSION
In this study, BNP and RVEDVI measurements did not correlate with BV status as determined by the BVA-100 Analyzer in critically ill surgical patients in whom PAC insertion was used to guide treatment. These results suggest that BNP and RVEDVI, in common use clinically, are not precise indices of intravascular volume status although these parameters may reflect cardiac preload. The importance of this study is that clinicians must be cognizant of the limitations of currently available modalities that are being used in clinical decision making to optimize volume loading.
A number of investigators have demonstrated that BNP has diagnostic value in subjects with acute heart failure. In patients with dyspnea, for example, a serum BNP concentration greater than 100 pg/mL has been shown to be the strongest independent predictor of heart failure as the underlying etiology. Furthermore, heart failure is very unlikely in patients with BNP levels less than 100 pg/mL and highly likely with levels greater than 500 pg/mL (90% positive predictive value). 32 This corpus of knowledge, regarding the relationship between BNP and heart failure, led a number of investigators to plausibly evaluate whether BNP can be used as a surrogate marker of ventricular function. Despite the fact that ventricular stretch is a major stimulus of BNP release, a close correlation between BNP and filling pressures (PAOP and left ventricular end-diastolic pressures) has not been demonstrated in the published literature. 22 A confounding feature is that there are a number of known cardiac and noncardiac causes of BNP elevations.
18Y23 Previous studies have also reported that BNP does not correlate well with BV, which may be a result of lag time between BV changes and BNP production by cardiac myocytes. 33, 34 Similar confounders may have contributed to the lack of correlation found between BNP concentrations and BV values in this study. It would have been interesting to further stratify subjects according to the presence or absence of congestive heart failure, to determine if there was a relationship between BNP and BV values in this cohort of subjects, but the sample size in the current study was too small to permit meaningful derivation of conclusions.
RVEDVI is a volumetric, as opposed to a pressure, measurement that is an accurate indicator of the preload supplied to the right ventricle. As borne out in the scientific literature, this cardiac parameter more closely correlates with CI than the traditionally used parameter of the PAOP, in patients with sepsis, ARDS, traumatic injuries, and in those receiving mechanical ventilation. 25 Although the ability to measure RVEDVI was available since 1989, the advent of continuous monitoring of this parameter has resulted in a resurgence of interest in evaluating the merits of this hemodynamic variable. 35 It is of significance that in the past, the correlation between RVEDVI and CI was attributed in part to mathematical coupling. However, Nelson et al. 36 compared RVEDVI and CI prospectively using two independent methodologies and demonstrated that mathematical coupling did not account for the correlation between RVEDVI and CI.
In our study, RVEDVI measurements poorly correlated with BV values. The reason for the lack of association between RVEDVI and BV is unclear, but similar to BNP, there are a number of cardiac and noncardiac factors, such as pulmonary hypertension, respiratory failure, pulmonary embolism, and ARDS, which can influence this measurement. 37 Similar to the consideration for subgroup analysis in the evaluation of the relationship between BNP and BV, the sample size in the current study did not allow for meaningful analysis of the effect of ARDS on RVEDVI. Nonetheless, taken collectively, these data strongly suggest that BNP and RVEDVI should not be used to guide fluid management in this group of surgical ICU patients, consistent with the findings of other investigators.
12Y15
There are several limitations of this study. First, our study population is not homogeneous, which may have affected our results. In the ICU setting, it is a challenge to control for all patient variables and for all confounders that can affect BNP concentrations, RVEDVI, and BV measurements. Second, our study only compared static variables. We did not examine dynamic, temporal changes in BNP and RVEDVI because BV fluctuated over time. Prevailing literature shows that BNP and RVEDVI may be useful measures of volume responsiveness, and measurement of temporal changes in BNP and RVEDVI conceivably could have shown better correlation with changes in BV values over time. Finally, we did not assess outcomes, but in the larger prospective randomized trial, we did show differences in outcome, where patients who randomized to the BV arm were treated based not on BNP values but on BV values. 1 Since the majority of our patients had severe sepsis/septic shock (42%), traumatic injuries (25%), and ARDS (17%), BNP may not be a useful guide for fluid management in this cohort of ICU patients, in contrast to cardiac patients. 33, 34 In summary, the impact of BNP and RVEDVI measurements on augmenting the clinical determination of circulating BV seems limited at best, when applied to critically ill surgical subjects. No relationship was observed between these two parameters and intravascular volume status in our study.
Investigators have yet to identify a rapid, accurate, simple, and generalizable method for estimating intravascular volume status using surrogate markers, to ultimately direct fluid management in the ICU setting, and the evaluation of BV measurements in this regard warrants further study. 
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